Orion published Financial Statement Release for 2019 on Wednesday, 5 February 2020. The release, presentation material and link to live webcast recording are available here.
|3/19/2020||Orion cancels its Annual General Meeting on Wednesday 25 March 2020 and postpones it to a later date|
|3/5/2020||Orion Corporation: Change in Orion Group Executive Management Board as of 1 April 2020|
|3/2/2020||Orion Corporation: Transfer of 94,317 own B shares on 2 March 2020|
|3/2/2020||Orion Group Financial Statement documents 2019 and Corporate Governance Statement published|
|2/13/2020||Tero Närvänen is appointed Orion's new Vice President Quality Management as of 1 May 2020|
|1/31/2020||Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer|
|1/30/2020||Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer|
|1/23/2020||Marketing authorization granted for darolutamide in Japan|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.